Valuation: ARRD RESE

Market Cap 1.19TCr 1.04TCr 964.77Cr 885.78Cr 1.67TCr 1,13800Cr 1.7TCr 11TCr 4.46TCr 57TCr 4.48TCr 4.38TCr 1,90000Cr P/E 2026 *
-26.1x
P/E 2027 * -19.4x
Enterprise Value 1.1TCr 952.03Cr 886.13Cr 813.58Cr 1.54TCr 1,04500Cr 1.56TCr 10TCr 4.1TCr 52TCr 4.11TCr 4.02TCr 1,74500Cr EV / Sales 2026 *
25x
EV / Sales 2027 * 34.4x
Free-Float
94.54%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 56 01/12/2007
Director of Finance/CFO - 13/05/2025
Chief Tech/Sci/R&D Officer - 01/08/2022
Director TitleAgeSince
Chairman 56 -
Director/Board Member 66 19/08/2010
Director/Board Member 66 19/12/2011
Change 5-day change 1-year change 3-year change Capi.($)
+2.35%+2.74%+33.41%+79.20% 5.65TCr
-0.21%-7.38%+25.34%+63.02% 5.36TCr
-2.44%+1.40%-15.74%-16.80% 2.29TCr
-2.85%-7.78%-8.09%+346.36% 2.14TCr
+2.49%-0.92%+20.31%-12.15% 2.03TCr
+0.79%-1.06%+29.29%-33.32% 1.76TCr
+0.58%-5.88%+16.30%+540.37% 1.47TCr
-5.25%-4.23%+46.41%+169.05% 1.33TCr
+3.41%-6.61%+163.08%+280.43% 1.35TCr
Average -0.13%-3.79%+34.48%+157.35% 2.6TCr
Weighted average by Cap. +0.23%-2.96%+28.67%+119.98%

Financials

2026 *2027 *
Net sales 44Cr 38Cr 36Cr 33Cr 62Cr 4.19TCr 63Cr 418.47Cr 164.24Cr 2.09TCr 164.78Cr 161.16Cr 6.99TCr 32Cr 28Cr 26Cr 24Cr 45Cr 3.06TCr 46Cr 306.06Cr 120.12Cr 1.53TCr 120.52Cr 117.87Cr 5.11TCr
Net income -46Cr -40Cr -37Cr -34Cr -65Cr -4.42TCr -66Cr -441.54Cr -173.29Cr -2.2TCr -173.86Cr -170.04Cr -7.38TCr -63Cr -55Cr -51Cr -47Cr -88Cr -6.02TCr -90Cr -601.56Cr -236.09Cr -3TCr -236.87Cr -231.67Cr -10TCr
Net Debt -97Cr -84Cr -79Cr -72Cr -136.35Cr -9.28TCr -138.46Cr -926.96Cr -363.8Cr -4.62TCr -365.01Cr -356.99Cr -15TCr -88Cr -77Cr -72Cr -66Cr -124Cr -8.44TCr -125.92Cr -843.01Cr -330.86Cr -4.2TCr -331.95Cr -324.66Cr -14TCr
Logo ARRD RESE
Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them. The Company's therapies, using a broad portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, trigger the RNA interference (RNAi) mechanism to induce rapid, deep and durable knockdown of target genes. Its Targeted RNAi Molecule (TRiMTM) platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting while being structurally simple. It is focused on various therapeutic areas, such as cardiometabolic, pulmonary, liver, neuromuscular and others. It has over 18 discovered drug candidates in clinical trials ranging from early stage (Phase I) to late stage (Phase III). The Company's pipeline products include plozasiran, zodasiran, olpasiran, ARO-RAGE, SRP-1002, GSK4532990, fazirsiran, daplusiran/tomligisiran, ARO-CFB, ARO-INHBE, ARO-C3, ARO-PNPLA3, SRP-1001 (ARO-DUX4), SRP-1003 (ARO-DM1), SRP-1004 (ARO-ATXN2), and others.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-